Lutetium Lu177 Dotatate comment watch save
BreastfeedingPediatric

  • TRADE NAME: Lutathera
  • INDICATIONS: Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (with octreotide)
  • CLASS: Radiopharmaceutical, Somatostatin analog
  • HALF-LIFE: 7 days
  • FDA APPROVAL DATE: 01/26/2018
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known
  • PREGNANCY: Can cause fetal harm

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top